Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab

被引:0
|
作者
Rossi, Settimio [1 ]
Gesualdo, Carlo [1 ]
Marano, Ernesto [1 ]
Perrotta, Raffaele [2 ]
Trotta, Maria Consiglia [3 ]
Del Giudice, Antonio [1 ]
Simonelli, Francesca [1 ]
机构
[1] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Naples, Italy
[2] G Rummo Hosp, Eye Unit, Benevento, Italy
[3] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy
关键词
age-related macular degeneration; intravitreal injection; brolucizumab; real-life; neovascularization; NATURAL-HISTORY; RANIBIZUMAB; AFLIBERCEPT; PROGRESSION; PREVALENCE; MANAGEMENT; RISK;
D O I
10.3389/fmed.2024.1467160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy. The aim of this study is to provide the real-life anatomical-functional and safety results, after 1 year of treatment experience with Brolucizumab. Methods: This is a retrospective observational real-life study in which 44 patients (44 eyes) diagnosed with nAMD and treated with Brolucizumab were enrolled. We identified two groups: group 1 (24 treatment-na & iuml;ve eyes) that received a loading dose of 3 monthly intravitreal injections of Broluciziumab 6 mg (0.05 mL solution) + Q8w/Q12w regimen, and a Group 2 (20 non-na & iuml;ve eyes) which performed 1 injection + ProReNata (PRN) scheme. Monthly, all participants underwent comprehensive ophthalmological evaluation until 12 months follow-up. Results: We observed a significant improvement in best corrected visual acuity (39 +/- 15 L vs. 30 +/- 17 L; p < 0.01) and central retinal thickness (265 +/- 89 mu vs. 360 +/- 129 mu; p < 0.0001) at the end of follow-up without any differences between treatment-na & iuml;ve and non-na & iuml;ve patients. These results were obtained with a low number of injections (3.7 +/- 1.9) with only one case of intraocular drug-related adverse event. Finally, the presence of subretinal hyperreflective material correlates with lower visual recovery. Discussion: Our findings highlight the efficacy of Brolucizumab in managing wet-AMD and suggest its role for long-term efficacy in stabilizing retinal exudation and fluid accumulation, resulting in improved visual prognosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Intravitreal bevacizumab for neovascular age-related macular degeneration
    Ladewig, M. S.
    Ziemssen, F.
    Jaissle, G.
    Helb, H. -M.
    Scholl, H. P. N.
    Eter, N.
    Bartz-Schmidt, K. U.
    Holz, F. G.
    OPHTHALMOLOGE, 2006, 103 (06): : 463 - +
  • [42] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [43] Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
    Droege, Katharina M.
    Muether, Philipp S.
    Hermann, Manuel M.
    Caramoy, Albert
    Viebahn, Ulrike
    Kirchhof, Bernd
    Fauser, Sascha
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (05) : 1281 - 1284
  • [44] Intravitreal bevacizumab (avastin) in treatment of neovascular age-related macular degeneration
    Lazic, Ratimir
    Gabric, Nikica
    Dekaris, Iva
    Saric, Borna
    Gavric, Morena
    COLLEGIUM ANTROPOLOGICUM, 2007, 31 : 77 - 81
  • [45] Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
    Katharina M. Droege
    Philipp S. Muether
    Manuel M. Hermann
    Albert Caramoy
    Ulrike Viebahn
    Bernd Kirchhof
    Sascha Fauser
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251 : 1281 - 1284
  • [46] One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups
    Seungbum Kang
    Young-Jung Roh
    Japanese Journal of Ophthalmology, 2009, 53 : 389 - 395
  • [47] One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups
    Kang, Seungbum
    Roh, Young-Jung
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2009, 53 (04) : 389 - 395
  • [48] Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study
    Bashshur, Ziad F.
    Haddad, Zeina A.
    Schakal, Alexandre R.
    Jaafar, Rola F.
    Saad, Alain
    Noureddin, Baha' N.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) : 59 - 65
  • [49] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Hikaru Ota
    Jun Takeuchi
    Yuyako Nakano
    Etsuyo Horiguchi
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Japanese Journal of Ophthalmology, 2022, 66 : 278 - 284
  • [50] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Ota, Hikaru
    Takeuchi, Jun
    Nakano, Yuyako
    Horiguchi, Etsuyo
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (03) : 278 - 284